Dr. Lanzkron is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1015 Chestnut st
Philadelphia, PA 19107Phone+1 215-955-8444
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1994 - 1996
- University of MarylandResidency, Internal Medicine, 1991 - 1994
- Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
- MD State Medical License 1994 - 2026
- PA State Medical License 2024 - 2024
- TX State Medical License 1997 - 2000
- American Board of Internal Medicine Hematology
Clinical Trials
- Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) Start of enrollment: 2007 Sep 01
- A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients Start of enrollment: 2010 Jan 01
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease.Charles R Jonassaint, Christina M Lalama, C Patrick Carroll, Sherif M Badawy, Megan E Hamm
Blood Advances. 2024-12-24 - Longitudinal outcomes of chronically transfused adults with sickle cell disease and a history of childhood stroke.Jennifer M Jones, Julia Wool, Elizabeth P Crowe, Evan M Bloch, Lydia H Pecker
Transfusion. 2024-12-01 - Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management.Marti Goldenberg, Sophie Lanzkron, Lydia H Pecker
Expert Review of Hematology. 2024-12-01
Journal Articles
- Correction to: Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical RecordSophie Lanzkron, Monica E Peek, Mary Catherine Beach, Anna P Goddu, Somnath Saha, Mustapha O Saheed, Journal of General Internal Medicine
- A Phase 3 Trial of L-glutamine in Sickle Cell DiseaseRita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine
Abstracts/Posters
- Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of HydroxyureaSophie M. Lanzkron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the USSophie M. Lanzkron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Quality Improvement Initiative: Improving Time to First Dose in a Sickle Cell Infusion CenterSophie M. Lanzkron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Sickle Cell Disease61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease60th American Society of Hematology Annual Meeting - 12/2/2018
- Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease60th American Society of Hematology Annual Meeting - 12/1/2018
- Join now to see all
Press Mentions
- Philadelphia Health Providers and Patients Seek a New Treatment Roadmap for Sickle Cell Disease After Drug RecallOctober 10th, 2024
- Doi: 10.32481/djph.2022.10.004October 1st, 2022
- Sickle Cell Patients Face a Double Whammy: Systemic Racism and a Crippling DiseaseJune 7th, 2022
- Join now to see all
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/sophie-lanzkron
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: